TL;DR — For U.S. investors who want Korean biotech. Samsung Biologics, Celltrion, Yuhan, Alteogen and Samsung Epis Holdings have no ADR listed on a U.S. exchange. From a U.S. account you reach four of them through EWY, where they add up to 4.04% of the fund (Nov. 16, 2026), or you buy them in Seoul — and Seoul holders of Samsung Biologics just faced a rights decision on a ₩2.66 trillion (about $2.0 billion) share offering.
I’m Mr. Gat, and this is TheGatBull.
Not financial advice.
Can you buy Korean biotech stocks from a U.S. account?
Of the routes we confirmed, the only way to own the shares themselves is on the Seoul exchange. None of Samsung Biologics (207940), Celltrion (068270), Yuhan (000100), Alteogen (196170, KOSDAQ) or Samsung Epis Holdings (0126Z0) has an ADR (American depositary receipt) on a U.S. exchange. A U.S. account can hold four of them inside EWY, the iShares MSCI South Korea ETF, at 4.04% combined, or buy them directly through a broker with Korea Exchange (KRX) access.
Your Door — for a U.S. account that wants Korean biotech exposure.
- If you hold EWY: biotech and healthcare are 4.04% of the fund. That is too small to call a sector bet; information technology is 47.54%.
- If you hold Seoul shares directly: when the company runs a shareholder-allotment offering like Samsung Biologics’ this year, you receive subscription rights and have to act on them yourself — subscribe, sell the rights, or do nothing and see your stake diluted.
Dates and times are Seoul time (KST) unless marked ET; in November, ET is 14 hours behind Seoul. Prices are KRX regular-session closes (3:30 p.m. Seoul). Dollar conversions are for scale only, at ₩1,333.0 per dollar, the press-reported Seoul 3:30 p.m. rate on Nov. 18, 2026.
Four terms. DART: Korea’s electronic corporate filing system, the counterpart of the SEC’s EDGAR. Record date: the date that decides which shareholders receive the new-share allotment. CDMO (contract development and manufacturing organization): a company that develops and makes drugs for other drug companies. Rights offering (in Korea, “shareholder allotment followed by a public offering of unsubscribed shares”): new shares are offered first to existing shareholders in proportion to their holdings; only the shares they do not take are sold to the public.
Five companies, two routes
| Company | KRX code | Market | U.S.-listed ADR | EWY weight (Nov. 16) | Nov. 18 close (KRX) |
|---|---|---|---|---|---|
| Celltrion | 068270 | KOSPI | None | 1.75% | ₩207,500 |
| Samsung Biologics | 207940 | KOSPI | None | 1.09% | ₩1,366,000 |
| Yuhan | 000100 | KOSPI | None | 0.60% | ₩80,100 |
| Alteogen | 196170 | KOSDAQ | None | 0.60% | ₩170,900 |
| Samsung Epis Holdings | 0126Z0 | KOSPI | None | Not held | ₩362,500 |
- Sources: EWY weights from iShares holdings (as of Nov. 16, 2026); closes are KRX regular-session closes on Nov. 18, 2026; ADR status from our list of Korea’s eight NYSE ADRs (SK hynix trades on Nasdaq as SKHY) — no biotech company is on it.
- Trading hours: the KRX regular session runs 9:00 a.m. to 3:30 p.m. KST, which is 7:00 p.m. ET the previous evening to 1:30 a.m. ET (November to March). It does not overlap with the U.S. regular session (9:30 a.m. to 4:00 p.m. ET).
- Samsung Epis Holdings is a biosimilar holding company split off from Samsung Biologics and listed in 2025. It is not in the iShares holdings as of Nov. 16.
One-line reading: Korean biotech inside EWY is four stocks and 4.04%. For a U.S. investor who wants Korean biotech, EWY is not a biotech product; it is an IT-heavy fund (IT is 47.54%) with a little biotech mixed in.
What Samsung Biologics does
It makes other companies’ drugs. In industry terms it is a CDMO. The closest U.S. anchor is Thermo Fisher Scientific’s contract-manufacturing business (Patheon). Not a perfect parallel: Thermo Fisher’s shareholders are widely spread, while Samsung affiliates own 73.61% of Samsung Biologics. That difference shows up directly in the rights offering below.
Three facts from the filings on the ₩2.66 trillion rights offering
1. How much, and who was asked first
Samsung Biologics’ board decided on the rights offering on Aug. 28, 2026, and payment was completed on Nov. 17 (DART 20261117800347).
| Item | Value |
|---|---|
| New shares issued | 2,270,000 |
| Issue price | ₩1,174,000 (about $881) |
| Amount raised | ₩2,664,980,000,000 (about $2.0 billion) |
| Shares before → after | 46,290,951 → 48,560,951 (+4.90%, our calculation) |
| New shares per existing share | 0.0392737657 (record date Oct. 6, 2026) |
| Rights certificates | Transferable; listed on the exchange |
| New-share listing date | Nov. 30, 2026 |
Sources: material-event report (rights offering decision, amended), DART 20261105000355; issuance result, DART 20261117800347. Dollar figures at the Seoul 3:30 p.m. rate of ₩1,333.0 on Nov. 18 (our calculation).
What matters is the method: shareholder allotment first, public offering of the leftovers second. New shares go to existing shareholders first, in proportion to what they own, and only the shares they decline are sold to the public. A typical U.S. follow-on offering runs the other way: the company sells new shares to new investors through underwriters, and existing shareholders usually have no right to buy first.
2. Who bought
| Stage | Subscribed | Result |
|---|---|---|
| Employee stock ownership association + existing shareholders (including requests for extra shares) | 2,198,146 shares | 96.83% |
| Leftover (unsubscribed) shares | 71,854 shares | Sent to the public offering |
| Public offering | 9,745,071 shares subscribed | 13,562.32% (about 136 times the shares available) |
Sources: subscription results, DART 20261111800082 and 20261116800009.
The largest shareholders’ numbers changed on the same date, Nov. 17 (DART 20261118800334). Samsung C&T received 782,818 new shares and Samsung Electronics 567,503. Each matches its own holding multiplied by 0.0392737657 — both took their full allotments, by our calculation. The stake of the largest shareholder and related parties went from 74.30% to 73.61%, because the total share count grew 4.90%.
Under the Gat. Existing shareholders were asked first, but about three-quarters of the stock that got the first offer belonged to affiliates such as Samsung C&T, Samsung Electronics and Samsung Life (largest shareholder and related parties: 74.30%, as reported on Nov. 2, 2026). Samsung C&T and Samsung Electronics took their full allotments, and after the shareholder round only 71,854 shares were left for the public. Bids for them came to about 136 times the amount available. Of this roughly $2.0 billion raise, the public offering got about 3% of the new shares (our calculation).
3. Where the money goes
All of the proceeds are earmarked for “acquisition of another company’s securities”: PolyPeptide Group AG, a peptide CDMO listed on the Swiss stock exchange (DART 20261106000001).
- Tender offer price (an offer to buy shares directly from PolyPeptide’s shareholders): CHF 44.31 per share. Final acceptance: 97.98% (32,350,302 shares). The rest is to be acquired through a squeeze-out (a forced buyout of the remaining holders) under Swiss law to reach 100%. Expected share-transfer date: Dec. 31, 2026.
- The target’s 2025 results as written in the filing: revenue of ₩669.2 billion and a net loss of ₩36.1 billion (consolidated, end-2025, converted at the July 16, 2026 exchange rate).
- The filing states the acquisition amount as ₩2.706 trillion at the July 16, 2026 exchange rate. Because that uses a different exchange-rate date from the ₩2.665 trillion raised, we do not subtract one from the other to compute a “shortfall.” The filing says only that if amounts change during the process, the company will use its own funds.
Celltrion moved the other way
In the same autumn, Celltrion reduced its share count instead of increasing it.
- Decision to cancel 544,299 treasury shares (Sept. 16, 2026; scheduled cancellation date Sept. 30; DART 20260916800015), stated purpose “share price stabilization and shareholder value enhancement.”
- Decision to buy back ₩100 billion (about $75 million) of its own shares on the market (Oct. 26, 2026; buying period Oct. 27, 2026 to Jan. 26, 2027; DART 20261026000084).
- Largest shareholder (Celltrion Holdings) and related parties: 33.19% (as of Oct. 27, 2026; DART 20261027000365).
Samsung Biologics asked existing shareholders for more money, and Celltrion reduced its share count. Both moves are recorded in Seoul filings with dates and numbers — and we found little of either in English-language primary sources.
What this rights offering says about the Korean market
This is our reading. In a large Korean company’s rights offering like this one, the deciding question is less about which new investors buy than about what existing shareholders do. The law gives existing shareholders the first right to buy, and lets that right (the rights certificate) trade on the market. But in a company whose affiliates own 73.61%, most of those rights go to the affiliates. So the question “subscribe, sell the rights, or hold” is a live one mainly for investors in the remaining roughly 26% (shares outside the largest-shareholder group, our calculation) — foreign direct holders and funds such as EWY.
Whether EWY received and exercised Samsung Biologics rights as of the Oct. 6 record date cannot be confirmed from iShares’ public data. What can be confirmed: as of Nov. 16, EWY held 206,593 Samsung Biologics shares. Whether that number changes after the new shares list on Nov. 30 is what to watch.
What to watch
- Nov. 30, 2026 — 2,270,000 new Samsung Biologics shares list (shares outstanding up 4.90%). The Nov. 18 close of ₩1,366,000 was 16.35% above the ₩1,174,000 issue price (our calculation).
- Dec. 31, 2026 (expected) — PolyPeptide share transfer (settlement). The filing says the date may change depending on regulatory approvals.
- Jan. 26, 2027 — end of Celltrion’s ₩100 billion buyback period; watch whether a new cancellation filing follows.
- EWY holdings — how the 206,593 Samsung Biologics shares (Nov. 16) change after Nov. 30.
- Risk, in one line: the acquisition target posted a 2025 net loss (₩36.1 billion), and Samsung Biologics closed 30.48% below its Jan. 15, 2026 closing high of ₩1,965,000 — while the KOSPI was up 20.25% year to date (KRX closes).
Buying Korean biotech from the U.S.
- Access: no U.S.-listed ADR for any of the five; the routes are EWY (four of them, 4.04% combined) or a broker with KRX access. For the general routes into Korea, see how to buy Korean stocks from the U.S.; for a single-stock walkthrough, see how to buy SK hynix stock from the U.S.
- U.S. anchor: a U.S. follow-on offering, where existing shareholders usually get no first right to buy. Not a perfect parallel: in Korea the first right is the default for this method, and the rights certificate itself trades on the exchange.

The bottom line
This is our reading. A U.S. account has two routes we could confirm to Korean biotech. Through EWY you hold 4.04% of it as a small add-on; by buying in Seoul you have to answer the company’s own decisions directly — this time, a ₩2.66 trillion rights offering. The fact this company shows: in a Korean rights offering like this one, existing shareholders get the first offer, and when affiliates hold three-quarters of the stock, that offer is a real choice mainly for the other roughly 26%.
The Seoul Seven · how this piece was checked: ✓ Korean original · ✓ Dated sources · ✓ Seoul & New York time · ✓ Beyond EWY · ✓ U.S. anchor · ✓ What to watch · ✓ Corrections kept · what these mean
— Mr. Gat. Stay bullish. (Not a call to buy or sell.)
Related reading: Korea’s eight NYSE ADRs · How to buy SK hynix stock from the U.S. · MSCI Korea November review
FAQ
Can you buy Samsung Biologics stock in the U.S.?
There is no ADR on a U.S. exchange. You can hold it indirectly through EWY (1.09%, as of Nov. 16, 2026) or buy 207940 directly through a broker with Korea Exchange access.
Is Celltrion in EWY?
Yes. At 1.75%, it is the largest of the four Korean biotech and healthcare holdings in EWY (as of Nov. 16, 2026).
How much of EWY is Korean biotech and healthcare?
4.04%: Celltrion 1.75%, Samsung Biologics 1.09%, Yuhan 0.60% and Alteogen 0.60% (as of Nov. 16, 2026).
What is Samsung Biologics’ 2026 rights offering?
A ₩2.66 trillion rights offering of 2,270,000 new shares at ₩1,174,000 each, offered first to existing shareholders. Payment was completed on Nov. 17, and the new shares are scheduled to list on Nov. 30. The money is earmarked for the acquisition of Switzerland’s PolyPeptide.
What are subscription rights in a Korean rights offering?
The right of existing shareholders to buy new shares first, in proportion to their holdings. In Samsung Biologics’ case, these rights (rights certificates) could be bought and sold on the exchange.
Sources
- DART, Samsung Biologics: rights offering decision (amended) 20261105000355 · subscription results 20261111800082 and 20261116800009 · issuance result 20261117800347 · largest-shareholder holdings change 20261118800334 · acquisition of PolyPeptide shares (amended) 20261106000001.
- DART, Celltrion: share cancellation 20260916800015 · treasury share purchase 20261026000084 · large-holding report 20261027000365.
- iShares MSCI South Korea ETF (EWY) holdings, as of Nov. 16, 2026.
- Prices: Yahoo Finance chart data (KRX regular-session closes, Nov. 18, 2026; vendor data, not exchange-published figures).
- Won-dollar rate: ₩1,333.0, Seoul 3:30 p.m. close, Nov. 18, 2026 (Asia Economy, TokenPost; press).
How sure are we?
| Item | Confidence |
|---|---|
| Offering size, price, share counts, subscription results, affiliate allotments, PolyPeptide terms, Celltrion actions | ✅ Company filings on DART |
| EWY weights and Samsung Biologics share count in EWY | ✅ iShares holdings file, as of Nov. 16, 2026 |
| No U.S.-exchange ADR for the five companies | Our check of U.S.-listed Korean ADRs; over-the-counter listings not checked |
| Closing prices, YTD and high-to-close moves, percentages and dollar figures | Vendor data (Yahoo), KRX close; percentages and conversions are our calculation |
| Nov. 18 won-dollar rate | ⚠️ Press-reported |
| Whether EWY received or exercised Samsung Biologics rights | Not confirmed |
Not financial advice. TheGatBull is an independent publication; nothing here is a recommendation to buy or sell any security.
Written by Mr.Gat — TheGatBull
Korean market coverage from a Seoul-metro-based operator with 15 years of personal investing experience, who reads the filings in the original language. Every price on this site is the KRX regular-session close (15:30 Seoul); every figure states whether it came from a primary filing, the press, or our own calculation. Drafts are AI-assisted, then verified against the original Korean documents and edited by a human before publishing.
Found an error? Tell us — corrections get priority. How we work →